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6INTRODUCTION
DIASTOLIC DYSFUNCTION:
Diastolic dysfunction is an abnormality of diastolic distensibility, filling, 
or relaxation of the left ventricle and the heart fills more slowly, 
asynchronously or only with an increase in filling pressure.
HEART FAILURE :
Heart failure (HF) is generally defined as inability of the heart to supply 
sufficient blood flow to meet the body's needs.
Heart failure is a common, costly, disabling, and potentially deadly 
condition.
Around 2% of adults suffer from heart failure, but in those over the age 
of 65, this increases to 6–10% [1,2] , the condition usually worsens with time. 
Heart failure is the leading cause of hospitalization in people older than 
65. [3] Although some people survive many years, progressive disease is 
associated with an overall annual mortality rate of 10%. [4]
Heart failure [HF] is classified in to
 HF with decreased ejection fraction
 HF with normal ejection fraction [DHF]
7DHF has a prevalence of almost 50 % of total heart failure, and is 
increasing in incidence every year thus causing a high burden to the 
community and health care. [5]
Eventhough earlier studies showed better prognosis for DHF, recently
concluded various studies have indicated morbidity and mortality similar to HF 
with decreased EF [6,7] .
In addition to the traditional causes of DHF such as hypertension, aortic 
stenosis and others, Diabetes as a cause of Diastolic dysfunction and hence to 
DHF has an increased recognition in recent years. 
Various studies has shown a prevalence of diastolic dysfunction to be 55 
to 65 % among Diabetic individuals [120,189]. 
With Diabetes increasing in incidence, with increase in longevity, 
sedentary lifestyle and obesity, Diabetes will form a major cause of DHF, 
particularly, these individual risk factors most often co-exist. 
With this background presence of Diastolic dysfunction in diabetic 
patients was studied in our hospital. 
8AIM OF STUDY
1) To find out the Diastolic dysfunction among the Diabetes mellitus 
patient attending Diabetic OPD in GRH. 
2) To find out whether the following parameters affect the occurrence of 
Diastolic dysfunction in Diabetic individuals.
a. Age
b. Sex
c. Duration of Diabetes
d. Smoking
e. Alcohol
f. Body Mass Index
g. Diabetic Retinopathy
h. Proteinuria
i. Dyslipidemia
9REVIEW OF LITERATURE
Physiology of diastole
Diastole includes the part of the cardiac cycle starting at the aortic valve 
closure – when LV pressure falls below aortic pressure and finishing at the 
mitral valve closure. 
A normal LV diastolic function may be clinically defined as the capacity 
of the left ventricle to receive a LV filling volume able, in its turn to guarantee 
an adequate stroke volume, operating at a low pressure regimen. 
In merely descriptive terms, diastole can be divided in 4 phases [10]: 
1. Isovolumetric relaxation, period occurring between the end of LV 
systolic ejection (= aortic valve closure) and the opening of the mitral valve, 
when LV pressure keeps going its rapid fall while LV volume remains constant. 
This period is mainly attributed to the active LV relaxation, with a lower, 
variable contribution of elastic recoil of the contracted fibers; 
2. LV rapid filling, which begins when LV pressure falls below left atrial 
pressure and the mitral valve opens. During this period the blood has an 
acceleration which achieves a maximal velocity, directly related to the 
magnitude of atrio-ventricular pressure, and stops when this gradient ends. This 
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period represents a complex interaction between LV suction (= active 
relaxation) and visco-elastic properties of the myocardium (= compliance);
The above figure shows cardiac cycle events occuring  in the left ventricle.
3. Diastasis, when left atrial and LV pressures are almost equal and LV 
filling is essentially maintained by the flow coming from pulmonary veins –
with left atrium representing a passive conduit – with an amount depending of 
LV pressure, function of LV "compliance"; 
4. Atrial systole, which corresponds to left atrial contraction and ends at 
the mitral valve closure. This period is mainly influenced by LV compliance, 
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FIGURE 1: Grading of diastolic dysfunction from normal to severe 
dysfunction (grade 3-4), evaluated by Pulse Wave (PW) Doppler of mitral 
inflow. Normal: DT 140-240 msec; E/A 0.75-1.5. Grade 1: DT> 240 msec, E/A 
<0.75. Grade 2: DT 140-240 msec, E/A 0.75-1.5. Grade 3-4: DT < 140 msec, 
E/A > 1.5; in grade 3, the E/A ratio is reversible, when compared to grade 4, 
with the pre-load changes.
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FIGURE 2 : Diagramatic representation - Grading of diastolic dysfunction (N, 
G1, G2, G3)
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FIGURE 3: Normal trans–mitral-valve spectral Doppler flow pattern. The E-
to-A-wave ratio is approximately 1.4 to 1.0.
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FIGURE 4 : Trans–mitral-valve Doppler flow tracing in a patient with mild 
diastolic dysfunction (abnormal relaxation). The E-to-A-wave ratio is less than 
1.0.
FIGURE 5: Trans–mitral-valve Doppler flow pattern in a patient with severe 
(restrictive) diastolic dysfunction. The E-to-A-wave ratio is abnormally high, 
and the A-wave velocity is extremely low.
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but depends also by the pericardial resistance, by the atrial force and by the 
atrioventricular synchronicity (= ECG PR interval). 
Cardiac catheterization allows to assess the pressure-volume relation 
along the overall cardiac cycle. Among the various hemodynamic 
measurements, τ (= time constant of the isovolumic pressure decline) and 
DP/DV ratio, expression of LV end-diastolic myocardial stiffness, are the main 
invasive measurements of LV diastolic function [10]. On the other hand, Doppler 
recording of transmitral and pulmonary venous flow measure - flow velocities 
and time intervals, whose variations occur in relation to analogous variations of 
left atrial and LV pressures [11,12]. Thus, Doppler parameters provide important 
information about dynamics of LV filling and LV diastolic properties during 
disease evolution or improvement [13]. 
Ultrastructural features of diastolic dysfunction
The extracellular matrix (ECM), corresponding to fibrillar collagen, is an 
important structure for processes of both myocardial contraction and 
relaxation. It facilities the arrangement of the cardiomyocytes into the most 
suitable allocation for the development of force and shortening, giving a 
substantial support to the maintenance of an effective myocardial performance 
[14]. 
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The myocardial remodelling is accompanied by changes of myocardial 
cell factors but also of the ECM where fibroblast proliferation, alteration of the 
collagen network and increase in interstitial and perivascular collagen are 
strongly promoted by renin-angiotensin-aldosterone system [15]. ECM has, 
therefore, to be considered a dynamic entity playing a fundamental role into the
myocardial adaptation to physiologic and pathologic stress [14]. ECM undergoes 
an intense turnover, due to balanced action of metalloproteases, proteolytic 
enzymes activated by several factors including also BNP, and tissue inhibitors 
counterbalancing the activity of metalloproteases [16]. Thus, if the collagen 
destruction alters both geometry and function of contractile myocardium 
throughout an upregulation of metalloproteases, on the other hand myocardial 
fibrosis occurs because of an imbalance where collagen deposition prevails 
over its degradation. 
According to the ultrastructural view, we can hypothesize two opposite 
pathologic conditions: the first one, when the collagen loss, e.g, after acute 
myocardial infarction, deprives myocardium of its indispensable support 
structure, thus inducing a reduction of myocardial systolic function; the second 
one, when the accumulation of the same collagen, main component of 
myocardial fibrosis, determines both systolic and diastolic myocardial 
dysfunction. In this context not only the total amount of collagen is main 
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determinant of LV diastolic stiffness but also distribution, configuration, 
disorganization of collagen fibers (crosshatching), and ratio of collagen type I 
to collagen type III play an important role [14]. 
Clinical, hemodynamic and diagnostic aspects of diastolic dysfunction:
Clinical Aspects :
In the clinical setting the coexistence of systolic and diastolic 
dysfunction in patients with symptomatic HF occurs very often. In fact, LV 
stiffness (or compliance) is related to the length of myocardial fibers, reflecting 
in its turn on LV end-diastolic dimensions. LV diastolic function, through the 
influence on left atrial and capillary wedge pressures, determines the onset of 
symptom in patients with prevalent LV systolic dysfunction too. In parallel to 
the ultra-structural level, the clinical progression of HF may follow two 
different routes. In the first one, as it happens after acute myocardial infarction, 
postinfarction LV dilation (= remodelling) leads to systolic dysfunction and/or 
systolic heart failure. In the second one, LV structural abnormalities (= LV 
concentric geometry) induce functional alterations of DD. When diastolic 
dysfunction becomes symptomatic – that is, when dyspnoea occurs – diastolic 
heart failure rises. The majority of patients affected by isolated diastolic HF 
show symptoms not at rest but in relation to stress conditions (II NYHA class). 
Symptoms can be induced or worsened by, firstly, physical exercise but also by 
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events as anaemia, fever, tachycardia and some systemic pathologies. In 
particular, tachycardia reduces the time needed for global LV filling, thus 
inducing an increase of left atrial pressure and consequent appearance of 
dyspnoea, because of accumulation of pulmonary extravascular fluid. 
The diagnosis of HF can be performed obviously by the simple clinical 
examination but the identification of the diastolic origin needs an instrumental 
assessment. In fact, the objective examination of patients with diastolic HF 
allows to notice the same signs occurring for systolic HF and even the thoracic 
X-ray can not be useful to distinguish the two entities. ECG can show signs of 
LVH, due to hypertensive cardiomyopathy or other causes. DD may be 
asymptomatic and, therefore, identified occasionally during a Doppler 
echocardiographic examination. 
ECHO-Doppler :
The diagnostic importance of this tool rises from the high feasibility of 
transmitral Doppler indexes of diastolic function, shown even in studies on 
population [17], such to be suitable and accurate also for serial evaluations over 
time. To date, standard Doppler indexes may be efficaciously supported by the 
evaluation of pulmonary venous flow[18] and by new ultrasound technologies as 
Tissue Doppler [19] and color M-mode derived flow propagation rate [20]. The 
application of maneuvers (Valsalva, leg lifting) [21,22] to Doppler transmitral 
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pattern and/or different combination of standard transmitral Doppler with the 
new tools (ratio between atrial reverse velocity duration and transmitral A 
velocity duration, ratio between transmitral E peak velocity and Tissue Doppler 
derived Em of the mitral annulus or flow propagation velocity [Vp]) are 
sufficiently reliable to predict capillary wedge pressure and to distinguish 
accurately variations of LV end-diastolic pressure [23,24]. Some of these tools are 
effective even in particular situations as sinus tachycardia [25] and atrial 
fibrillation[26] while the pulmonary venous flow or the Valsalva maneuver 
applied to transmitral inflow has to be preferred in the case of mitral valve 
prosthesis and aortic valve regurgitation, respectively [27]. In addition, Tissue 
Doppler is also able to "read" the percentage of myocardial fibrosis [28], primum 
movens of DD. Alone or, better, combined together, these tools permits to 
recognize normal diastole as well as to diagnose and follow the progression of 
DD from the pattern of abnormal relaxation (grade I of DD) until 
pseudonormal (grade II) and restrictive (grade III-IV) patterns. 
Hemodynamics :
By the hemodynamic point of view, the differences between diastolic 
and systolic HF are expressed by the pressure-volume loop [29]. When systolic 
HF occurs, increased LV filling pressures correspond to increased LV volumes, 
with a displacement of the loop upon and at right. In the case of diastolic HF, 
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the increase of LV filling pressures occur in the presence of normal or even 
reduced LV volumes, thus moving the loop up and to the left. It is obvious that 
in the more advanced stages of HF, diastolic and systolic dysfunction coexist.
Determinants of diastolic dysfunction: 
LV DD develops in several cardiac diseases [30] as well as in extra -  
cardiac pathologies involving the heart (accumulation diseases as amyloidosis, 
thyroid disorders, acromegaly and others) [31,32] and in myocardial ischemia due 
to coronary artery stenosis or even to isolated dysfunction of coronary 
microcirculation [33]. Till now, the main cause of DD is arterial hypertension 
[8,9,70]. Overweight and obesity, often coexisting with the same hypertension, 
deeply affects LV diastolic function, forcing the left ventricle to a working 
overload [34]. In this view, DD represents one of the cardiac consequences of 
pluri-metabolic syndrome, where arterial hypertension, obesity, glucose 
intolerance and hypertriglyceridemia cohabit in the same subject, having their 
common matrix in the insulin resistance. High levels of insulin resistance, 
often evident in arterial hypertension [35], are positively associated with the 
prolongation of isovolumic relaxation time, independent of LV geometric 
changes and of increased afterload[36]. 
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The alteration of diastolic isovolumic relaxation is probably due to an 
increment of intracellular calcium, which has been observed in insulin resistant 
hypertensives and is induced in its turn by an abnormal re-uptake of calcium by 
sarcoplasmic reticulum [37]. Also the hormones produced by adipose tissue, as 
leptin – involved into the control of body weight throughout food absorption 
and energy-giving cost – negatively affects LV diastolic function [38]. The 
association of arterial hypertension and diabetes mellitus worsens further 
Doppler indexes of LV diastolic function as shown into the population of the 
Strong Heart Study [39]. 
It is controversial whether LV DD is necessarily accompanied on the 
development of LVH or rises up independent of it [8,9,40-43,70]. It is true that DD 
is a direct sequence of pressure overload, associated to elevated 24-hour blood 
pressure [40] and even more to the increment of nighttime diastolic blood 
pressure [43]. Recent studies point out that the diastolic abnormalities of 
hypertensive patients are related to inappropriately high levels of LV mass, 
disproportionate to the hemodynamic load predicted by the individual body 
size and cardiac load, more than to the values of LV mass which traditionally 
define LVH [44]. Inappropriately high LV mass is a potent predictor of 
cardiovascular risk in hypertensive patients, in presence as in absence of clear 
cut LVH [45]. The concept of DD onset preceding the appearance of LVH is 
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consistent with the observation that BNP, whose levels grow gradually with the 
progression of DD grading (from abnormal relaxation until restrictive Doppler 
patterns) [46], are increased in patients with diastolic HF independent of the 
magnitude of LV mass [47]. Even a new ultrasound technology as Tissue 
Doppler supports the hypothesis of an early evidence of DD: myocardial DD 
(= Em/Am ratio < 1 at the level of multiple LV walls in the apical views) is 
detectable before the appearance of the abnormalities involving LV transmitral 
inflow and is uniform in non hypertrophic patients while it becomes prominent 
at the septum in presence of overt LVH [48]. It is now clear that diastolic HF is 
associated to both increase of collagen amount and LV concentric geometry [49]. 
This concept is further supported by the HyperGEN study where delayed LV 
relaxation is independently associated with concentric LV geometry in 
hypertensive patients including obese and diabetic patients [50].
Definition and classification criteria for diastolic HF: 
The evidence of acute HF in absence of overt LV systolic dysfunction 
raised by the experience of Gandhi and coworkers [51]: where hypertensive 
patients affected by pulmonary oedema, undergoing echocardiographic 
examination during the acute episode and after clinical stabilization 
respectively (1–3 day after), did not show significant variations of LV EF (50 ± 
15% and 50 ± 13% respectively, NS) and of wall motion score index between 
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the two examinations. This clinical condition, defined as heart failure with 
preserved systolic function or, better, with normal EF, has been made equal to 
isolated diastolic heart failure. A truly correct definition of this clinical entity 
should, however, be done on the grounds of direct estimation of LV diastolic 
function and establishment of reference normal values. Strong controversy has 
been developed in the previous years about this issue, with opposite scientific 
positions. 
The American point of view, corresponding to the Framingham Heart 
Study investigators, has sustained the concept that diastolic HF is "definite" 
only when an invasive hemodynamic assessment shows diastolic alterations in 
the temporal proximity of the acute episode  [52]. On the other hand, the 
European point of view (European Group on Diastolic Heart Failure)has 
defined diastolic HF according to criteria including clinical examination, 
echocardiographic assessment (normal EF) and Doppler indexes (derived by 
both transmitral inflow and pulmonary veins flow)[53]. 
Despite the obvious superiority of the invasive technique [54], it has to be 
taken into account that the need of cardiac catheterization for establishing a 
definite diagnosis of diastolic HF raises practical and even ethical issues. 
Practical issues are related to the low priority such examination would have in 
a cath-lab overloaded by coronary procedures and to the poor interest of 
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hemodynamists in the assessment of indexes of LV diastolic function. Ethical 
concern lies upon the fact that the present reliance on echo-Doppler 
examination of LV diastolic function makes cardiac catheterization an useless 
invasive procedure to this end, except very particular cases. Moreover, if it is 
true that the prevalence of abnormal Doppler indexes (from 38% of isovolumic 
relaxation time to 64% for deceleration time) is much lower to that showed by 
the more reliable invasive measurements (92 % for LV end-diastolic pressure 
and 79 % for τ) [55], is also true that this can be, at least partially, due to the 
confounding influence of physiologic variables as age [56] and heart rate[57]. In 
this view, reference normal values of Doppler indexes of LV diastolic function 
should be done considering ranges of both age and heart rate. 
It is now current opinion that the diagnosis of diastolic HF can be made 
even without measurement of diastolic function if three criteria are present: 
1)symptoms and signs of HF (Framingham criteria), 2) LV EF> 50%, and 3) 
ability to rule out mitral stenosis, pericardial disease, and non cardiac causes of 
dyspnoea, oedema and fatigue [58]. Recent evidences further sustain the definite 
role of Doppler echocardiography to diagnose diastolic HF [59,60]. 
To date, however, no certain definition of diastolic HF exists and the 
recognition of its existence is not unanimously accepted [49]. Studies performed 
by both standard Doppler echocardiography [61] and Tissue Doppler [62,63]
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demonstrated how sub-clinic alterations of myocardial systolic function are 
already overt in diastolic HF. Because of the use of LV EF is a rather 
insensitive indicator of true LV myocardial contractility, the assessment of LV 
long-axis function by the simple M-mode of the mitral lateral annulus could 
help to identify initial LV systolic dysfunction [64]. Finally, it has also to be 
taken into account how concomitant variables, including obesity, chronic 
obstructive lung disease and even myocardial ischemia,can be confounding 
factors leading to "false" diagnosis of diastolic HF, particularly in the elderly 
population [65].
Prevalence of diastolic HF: 
The studies performed until now have assessed above all the prevalence 
of HF with normal EF, using standard echocardiography without Doppler. In a 
first meta-analysis of 1995, the investigators of the Framingham Heart Study
[66] showed wide variability in the prevalence of this kind of HF (range = 13–
74%) while a subsequent study involving the Framingham offspring cohort 
pointed out a 51% prevalence of overall HF [67]. Very recently, Hogg et al 
collected ten "cross-sectional" studies on population, in the United States as in 
several European countries, and found very high variability of HF with normal 
EF. The explanation of this variability is related mostly to different age and 
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gender of participants. It has to be considered that this kind of HF is 
particularly frequent in the elderly population, occurs more often in the female 
gender and is associated much more with arterial hypertension and atrial 
fibrillation than to coronary heart disease [68]. The data collected between 1995 
and 1999 from Italian Network on Congestive Heart Failure (IN-CHF) are 
strongly consistent with these results [69]. The choice of different cut-off points 
for normal LV EF can be an additional reason of variability for the prevalence 
of diastolic HF in the above mentioned studies. As per recent studies HF with 
preserved EF constitutes almost half of the total [5].
Clinical course and Prognosis of DHF : 
Morbidity in Diastolic Heart Failure and Diastolic Dysfunction
It is well known that morbidity associated with diastolic heart failure is 
generally quite high [74,78-84]. The 1-year hospital readmission rate can approach 
50% in some series [71-73]. Patients with diastolic heart failure also tend to have 
frequent outpatient visits. For these reasons, the expenditures associated with
diastolic heart failure rival that of systolic heart failure [85]. In CHARM-
Preserved study [76], At a mean follow-up interval of 3.5 years, roughly 18% of 
the patients were admitted to the hospital for worsening heart failure, with 
4.2% having more than 3 admissions. In study conducted by Gottdiener et al 
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[86] patients with diastolic heart failure are at risk for nonfatal myocardial 
infarction and stroke. Increased morbidity has also been documented in 
patients with isolated diastolic dysfunction, as opposed to overt diastolic heart 
failure. Even studies that examine asymptomatic, relatively young patients with 
documented normal coronary anatomy suggest increased morbidity in the 
setting of diastolic dysfunction. 
Mortality in Diastolic Heart Failure and Diastolic Dysfunction: 
The mortality rate in patients with diastolic heart failure ranges from 5% 
to 8% annually, as compared with 10% to 15% in patients with systolic heart 
failure [72,73,87]. As shown in the study done by, Redfield et al [71], Isolated 
diastolic dysfunction carries an elevated mortality risk as does diastolic heart 
failure. 
Recent studies have also shown that the prognosis in diastolic 
dysfunction is the same as that in systolic dysfunction [6,7].
Prognostic Indicators : 
 Clinical Predictors
1. New York Heart Association class : Higher the class more the
mortality [75]
2. Renal function : worsening renal function as determined by 
glomerular filtration rate [88]  affects prognosis 
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3. Age : age is a strong predictor of mortality in diastolic heart
failure.[72,75,88]
 Brain Natriuretic Peptide
The level of brain natriuretic peptide (BNP), which correlates with 
diastolic abnormalities as seen on echocardiogram,[89] has received some 
attention as a possible predictor of outcome.
 Echo-Doppler 
Diastolic heart failure is a highly prevalent disease whose incidence will 
likely grow in the near future, considering the high prevalence of hypertension, 
diabetes, and obesity [77] as well as the increasing mean age Data concerning 
prognosis are accumulating from prospective cross-sectional and population-
based studies, especially those involving echocardiography. These data will 
likely improve the clinical approach to these patients by highlighting those at 
high risk for complications and mortality.
DIABETES AS A CAUSE OF DIASTOLIC DYSFUNCTION :
Diabetes is associated with increased cardiovascular complications, the 
most common of which are ischemic cardiomyopathy and left ventricular (LV) 
dysfunction. Diabetes is also associated with heart failure, mainly through its 
association with hypertension and coronary artery disease [90]. However, the 
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existence of a primary myocardial disease, “diabetic cardiomyopathy”, has 
been proposed as evidence has accumulated for the presence of myocardial 
dysfunction in diabetic patients in the absence of ischemic, valvular or 
hypertensive heart disease [91-97]. The existence of a diabetic cardiomyopathy 
was first proposed by Rubler et al in 1972 on the basis of postmortem findings 
[91]. Subsequently, abnormalities in both systolic and diastolic performance in 
diabetic subjects have been demonstrated in animal [98] and human studies [99-
103]. Diastolic dysfunction has been described as an early sign of this diabetic 
heart muscle disease preceding the systolic damage. The pathogenesis of this 
ventricular dysfunction remains unknown and has been somewhat controversial
[104]. 
Numerous studies have shown that impairment of the LV diastolic 
function may be detected in patients with diabetes. Diastolic LV abnormalities 
have been initially disclosed by cardiac catheterisation [99,105] and later by           
non – invasive methods. Regan et al [99] and Paillole et al [117], demonstrated in 
normotensive, diabetic patients without coronary artery disease, free of 
microangiopathy, and without clinical evidence of heart failure, increased left-
ventricular end-diastolic pressure, a decreased left-ventricular end-diastolic 
volume with a normal ejection fraction. Non-invasive studies subsequently 
demonstrated abnormalities of diastolic function in the diabetic population by 
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using several methods: abnormal time intervals by phonocardiograms [106,107], 
abnormal LV filling by standard and digitized echocardiography [108-111], 
radionuclide studies [112] and subsequently Doppler echocardiography [113,114]. Of 
note, impairment of the LV diastolic function was observed in patients free of 
diabetic complications, hypertension and symptomatic coronary artery disease. 
Diastolic abnormalities present in diabetic patients without diabetic 
complications or cardiovascular disease has been suggested as an earliest 
functional effect of a specific diabetic cardiomyopathy [115,116]. Various 
abnormalities in diastolic function, e.g. prolonged isovolumic relaxation 
period, delayed mitral valve opening and impairment in rapid diastolic filling, 
increased atrial contribution of LV filling, reduced E/A mitral ratio have been 
characteristics findings. In the large majority of studies, abnormalities of LV 
diastolic function have been demonstrated in diabetic patients with intact 
systolic function. Raev et al[116], demonstrated a high prevalence of diastolic 
dysfunction with preserved systolic function in asymptomatic, young, type 1 
diabetic patients. Diastolic dysfunction began 8 years after the onset of diabetes 
while systolic dysfunction was found much later, occurring after 18 years of 
diabetes duration. These studies have demonstrated a shift in the filling pattern 
from the early passive filling phase to the late atrially augmented filling phase. 
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Surprisingly, until recently, the existence of the pseudonormal LV filling 
pattern, a more advanced stage of LV diastolic dysfunction, was not evaluated 
in all the previous Doppler studies. Indeed, identification of a pseudonormal 
filling can be easily overlooked if preload reducing maneuvers (Valsalva 
maneuver, Glyceryl Trinitrate) or if new echo Doppler indices are not used. In 
very recent studies, a pseudonormal diastolic function was reported in 17 to 
28% of asymptomatic, normotensive type 2 diabetics using Valsalva 
maneuver[119,120] and with Glyceryl Trinitrate [121]. These studies led to the 
conclusion that LV diastolic dysfunction could be much more common than 
previously reported in this population. 
The influence of diabetic complications on LV diastolic dysfunction has 
been investigated in several studies. Varying results have been obtained 
between the severity of diabetic microvascular complications and LV diastolic 
dysfunction [103,106-109, 113,116, 122-126]. 
Diabetic Retinopathy : 
Studies performed in diabetic patients free of coronary artery disease, 
have demonstrated that patients with mild to severe retinopathy exhibited LV 
diastolic dysfunction (lower E/A values) compared to age-matched controls 
[114,127] or patients without retinopathy [123,128]. In the most recent report, [129] a 
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higher prevalence of retinopathy (49%) was encountered in patients with 
abnormal mitral filling pattern (E/A ratio < 1) compared to patients with a 
normal diastolic function (20%). This relation with retinopathy was however 
not constantly found. [118,130]
Nephropathy : 
In large number of studies, [123,131-133 ], there was a gradual decrease in 
E/A ratio in type 1 diabetic patients according to the presence of 
microalbuminuria and proteinuria. It was not constant, as shown in other 
studies.[129 ,134] 
Autonomic neuropathy : 
Cardiac autonomic neuropathy, affecting the sympathetic or 
parasympathetic sections or both, has been suggested to be a potential 
contributor to impaired diastolic function in several studies. As shown by 
Echocardiography,[118] correlation between DD and, 
1. Severity of cardiac autonomic neuropathy evidenced by radionuclide 
study.[112]
2. Myocardial sympathetic innervation function score derived from 
scintigraphy. [135]
3. Sympathetic dysfunction, evaluated clinically, by abnormal systolic 
blood pressure response to standing. [129]
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4. Parasympathetic neuropathy. [130, 136,137]
Relation with glycemic control
Initial studies performed in diabetic animals have revealed impaired 
myocardial contraction and relaxation and biochemical changes reversed after 
adequate insulin therapy [138,139], the degree of reversibility depending on the 
dose of insulin [140]. 
The relationship between diastolic dysfunction and glycemic control in 
diabetic patients is still a matter of debate. In a study individuals with type 1 
diabetes [141], severity of diastolic dysfunction, evaluated by computer assisted 
analysis of M-mode echocardiograms (time interval between minimal cavity 
dimension and mitral valve opening), was related to the long-term quality of 
metabolic control (mean value of HbA1c over the last two years).
Fiorina et al [142] demonstrated a reduction in the rate of diastolic 
dysfunction, evaluated using radionuclide ventriculography, in every uremic 
patient after a kidney - pancreas transplantation. This amelioration of LV 
diastolic dysfunction appeared to be positively associated with glycemic 
control.
Other studies have however shown a lack of correlation between 
impaired diastolic function and HbA1c levels, performed in type 1 diabetics 
[115, 103, 124, 143].
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In type 2 diabetics, prospective studies reached varying conclusions, a 
few studies shows a positive correlation between the good glycemic control 
and improvement in diastolic dysfunction. [127, 144, 145] 
On the other hand, some studies showed that improvement in glycemic 
control was not associated with changes in diastolic function even with 12 
months of follow-up [146-148].
Relation with severity of glycemic disturbance 
Few, small studies have shown relation of glucose homeostasis with 
Diastolic dysfunction.
In a study, subjects with normal glucose tolerance, with impaired 
glucose tolerance and with type 2 diabetes mellitus diagnosed by an oral 
glucose tolerance test according to the recommendations of the World Health 
Organization, they found early signs of diastolic dysfunction (assessed by E/A 
mitral flow ratio), not only in patients with diabetes but also in those with 
impaired glucose tolerance, independent of the confounding role of ischemia, 
body weight, and blood pressure[151,152]. They suggested that cardiac function is 
related to the concentration of glucose and HbA1c already below the threshold 
of diabetes. The limitation of the study is that done in a small population.
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Diastolic dysfunction and diabetes duration
Older studies showed that, Evidence of an alteration in LV diastolic 
function at an early stage of type 1 diabetes without correlation with specific 
complication, in which all patients were free of cardiovascular diseases and had 
diabetes mellitus for less than 5 years. However, the evaluation of diastolic 
function used an imperfect parameter assessed by M-mode echocardiography 
and phonomechanography. [144,149,150] 
Similar findings have been reported with Doppler echocardiography 
(E/A ratio), in newly diagnosed type 2 diabetic patients free of microvascular 
complications, without evidence of hypertension and coronary artery 
disease[103,143,146,147]. These observations of an impaired diastolic function in 
patients with newly diagnosed diabetes or with a short duration of the disease 
and with no microangiopathic complications suggest that this alteration may 
occur early in the history of type 2 diabetes and would not be related to 
microvascular complications. The lack of correlation between the occurrence 
of LV diastolic dysfunction and the duration of diabetes in these studies 
suggests that diabetic microangiopathy is not the only factor contributing to 
this dysfunction.
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Pathogenesis :
Besides the experimental findings in animal studies, numerous studies in 
humans have explored the association of diabetes with histopathological 
abnormalities. Alterations in intramyocardial coronary arteries, similar to those 
seen in other organs of diabetic patients have been reported. Endothelial 
proliferation and subendothelial hyaline thickening with PAS-positive material 
in the vessel wall have been described in some but not all patients with or 
without overt congestive heart failure [153]. Capillary basement membrane 
thickening and capillary microaneurysms have also been observed in hearts of 
diabetics [154,155]. In the study of Zoneraich et al [156] conducted in young 
normotensive type 1 diabetics, a small vessel disease was reported in 72% of 
diabetic patients while it was present in only 12% of non diabetic subjects. 
Interstitial accumulation of advanced-glycated end products (AGEs), which 
include collagen, elastin and other connective tissue proteins, as well as 
fibrosis in the myocardium have been reported in biopsy or post-mortem 
studies of human diabetic hearts [99, 157-160]. The mechanism of collagen 
accumulation in the diabetic myocardium seems to be due to impaired 
degradation rather than enhanced synthesis [161]. The interstitial abnormalities 
could explain an increase in end-diastolic stiffness as well as LV mass and 
contribute to the diastolic dysfunction [99]. In the less advanced forms of tissue 
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abnormality, the interstitial changes seem to predominate for some time and are 
associated with preserved cell morphology that is consistent with normal 
systolic function. As a potential diagnostic tool, it has been suggested that 
collagen accumulation in the extracellular matrix of the heart is responsible for 
abnormal acoustic properties of the myocardium in diabetic patients [123]. The 
coexistence of diabetes and hypertension, has been considered as a major factor 
in the expression of the abnormalities in human diabetic myocardium. This 
concept initially suggested in diabetic rats studies [162] was illustrated in the 
human study of Van Hoeven et al [160]. They demonstrated, in hearts obtained at 
autopsy, that interstitial and replacement fibrosis and myocytolitic necrosis 
were substantially more prominent in heart of hypertensive diabetics than in 
patients with isolated diabetes or hypertension. From these data emerged the 
concept that this association, which is very frequent in this population, is very 
likely to have synergistic relationship as a cause of LV dysfunction. The 
pathogenesis is however not completely elucidated, which explains why the 
relationship of type, duration and severity of the diabetes to the myocardial 
abnormalities still remain uncertain.
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Concept of Coronary Flow Reserve (CFR) :
Diabetes and coronary microvascular dysfunction : 
The alterations of myocardial composition and, thus, of diastolic 
properties and LV filling pressure might be mediated by changes in the 
coronary microcirculation. Microvascular damage experienced by the diabetic 
heart [205] may lead to myocardial cell injury and reactive fibrosis/ hypertrophy. 
Although focal microvascular alterations have not seemed sufficient to account 
for diffuse interstitial fibrosis [206], these observations looked at structure but 
not dynamics of coronary microvessels. Today, the function of coronary 
circulation may be evaluated by transthoracic echocardiography, by visualizing 
the distal left anterior descending artery [207-209], and by measuring coronary 
flow reserve (CFR) as hyperemic to the resting velocities ratio [207-209]. The 
CFR has excellent concordance with intracoronary Doppler flow wire-derived 
CFR [207], high feasibility [208], and reproducibility [208]. In the absence of 
epicardial coronary stenosis, impaired CFR indicates coronary microvascular 
dysfunction [209]. A reduction of CFR has been documented in both type 1 and 
type 2 DM and seems to be a direct consequence of elevated glycemia [210,211]. 
An alternative explanation is insulin resistance, which alters CFR during a cold 
pressure test, a completely endothelium-dependent stimulus [212]. Endothelial 
function, another possible determinant of CFR, is impaired in early DM [213]. 
39
Also, increased cardiac sympathetic activity may account for abnormal CFR in 
diabetic patients [214].
The link between coronary microvascular and diastolic dysfunction in diabetes:
Diastolic dysfunction is evident in type 1 diabetic patients free of CAD 
when CFR impairment is also detectable [214]. A similar relationship between 
the magnitude of CFR reduction and the degree of myocardial DD was found 
in uncomplicated hypertension [215], another condition characterized by 
impaired coronary microcirculation. This association is not surprising because 
coronary flow occurs predominantly during diastole. A change in the time 
constant of LV isovolumic pressure fall τ, measured by catheterization, is 
associated with decreased coronary flow even in patients without CAD [216]. 
Both reduced CFR and DD are associated with insulin resistance [213,217], with 
LV concentric remodeling/ hypertrophy [204,218], with disorders of the 
sympathetic nervous system [214], with abnormalities of the angiotensinrenin 
system [219], and with endothelial dysfunction [220]. We can, therefore, suppose 
that coronary microvascular damage plays a mechanistic role for DD [221] or 
even vice versa, considering DD as the main expression of myocardial fibrosis. 
Determinants of microvascular dysfunction in DM, such as hyperglycemia and 
insulin resistance, and factors including sympathetic overdrive, endothelial 
dysfunction, and LV concentric remodeling, also contribute to the development 
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of DD. Comprehensive transthoracic Doppler evaluation of diabetic patients 
should include assessment of diastolic function with estimation of LVFP by 
tissue Doppler, and of coronary microvascular function by CFR test. 
Clinical significance of LV diastolic dysfunction in diabetes :
Congestive heart failure is a major public health problem. Several 
epidemiological investigations have confirmed that up to half of patients in the 
community have heart failure due to diastolic dysfunction despite normal LV 
ejection fraction [163]. Some epidemiological and clinical arguments suggest 
that diastolic abnormalities may contribute to the high morbidity and mortality 
among diabetic patients. Indeed, in the community setting, data from the 
Framingham Heart Study have shown an increased incidence of congestive 
heart failure in diabetic subjects irrespective of coronary heart disease and 
hypertension [92]. It was also observed in patients enrolled in clinical trials of 
myocardial infarction. Despite similar LV systolic function, patients with 
diabetes have more pronounced heart failure symptoms, use more diuretics, 
and have an adverse prognosis compared with those without diabetes. One 
putative explanation for this discrepancy is diastolic dysfunction of the left 
ventricle [164]. The prognostic implications of diastolic dysfunction have been 
recently underlined. Diastolic dysfunction as rigorously defined by 
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comprehensive Doppler techniques is common, often not accompanied by 
recognized cardiac heart failure, and associated with marked increases in all-
cause mortality [165]. It has also been demonstrated that a reduced mitral E/A 
ratio is independently associated with increased all-cause mortality as well as 
cardiovascular mortality in a population based sample of middle-aged and 
elderly adults [166]. It is important to point out that these prognostic data 
included diabetic patients for whom no specific analysis was performed. By the 
way, to date, the prognostic impact of isolated diastolic dysfunction in diabetics 
is not clearly known. The impact of isolated diastolic dysfunction in diabetes 
only concerned exercise ability but did not address mortality evaluation. 
Indeed, some studies have demonstrated that in absence of LV systolic 
dysfunction, the impairment of LV relaxation can influence exercise tolerance 
[167, 168]. LV diastolic dysfunction was supposed to influence maximal treadmill 
performance and explain lower maximal performance observed in patients with 
type 2 diabetes. 
Treatment of DHF : 
Acute Diastolic Heart Failure :
When the patient presents in acute pulmonary oedema, the management 
is very similar to that of systolic heart failure. The use of oxygen, morphine, 
nitrates and diuretics to reduce venous congestion and relieve the hypoxia is 
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life saving. [169,170] However, even in this acute stage, awareness that this may 
be diastolic heart failure as opposed to systolic heart failure would influence 
our management. In patients who fit the diastolic heart-failure profile of being 
elderly, diabetic, hypertensive, African or Asian, we need to be cautious against 
too aggressive a diuresis. Aggressive diuresis may cause severe hypotension, as 
the left ventricle has a steep pressure-volume curve. Also, tachycardia is very 
poorly tolerated in diastolic heart failure, and in the presence of atrial 
fibrillation, early use of betablockers or calcium channel blockers is warranted. 
[171,172]
Intermediate-Term Treatment of Diastolic Heart Failure :
After appropriate diuresis and stabilisation of the patient, one has to 
consider the aetiology behind the diastolic heart failure in order to define the 
therapeutic strategy.
Long-Term Management :
While the acute - and intermediate - term management strategies have 
obvious clinical benefits or good evidence base, the long-term management of 
diastolic heart failure lies much more in the evidence-based vacuum. However, 
two large-scale randomised controlled trials have recently provided some 
evidence base for the treatment of diastolic heart failure.
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The Candesartan in Heart Failure - Assessment of Reduction in 
Mortality (CHARM) - Preserved study[173] use of candesartan added patients, 
had significantly fewer hospitalisations, and there was a trend towards 
reduction in the primary composite end point of heart-failure hospitalisation 
and death from cardiac cause.
The Seniors trial[174] use of nebivolol in diastolic heart failure with 
NYHA of II-IV, there was a significant reduction of the primary outcome of 
all-cause mortality and cardiovascular hospitalization. This implies that 
betablockade has identical benefit in diastolic heart failure as it does in systolic 
heart failure.
Left Ventricular Hypertrophy Regression :
Left ventricular hypertrophy regression (LVH) is thought to be one of 
the more reliable surrogate endpoints for diastolic heart failure[175-177]. 
Therefore, in terms of the left ventricular hypertrophy regression, ACEI, 
angiotensin receptor blockers, diuretics [178-180], calcium antagonists [181-182] and 
aldosterone antagonists [183-185] are useful agents. 
Non-Drug Therapy : 
It is important to recognise that weight loss, salt intake reduction and 
exercise can all help with left ventricular hypertrophy regression [186,187].
44
Cardiac rehabilitation programs are very helpful in the reconditioning of 
patients with diastolic heart failure [188]. 
Diabetic management :
Only proven treatment is long term good glycemic control and 
prevention of microvascular complications. 
What treatment modality - insulin or OHA'S, and which OHA to be 
selected still needs further studies.
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MATERIALS AND METHODS
PLACE OF STUDY : 
This study was conducted in Diabetology and Cardiac care unit GRH. 
PERIOD OF STUDY : 
From April 2009 to May 2010. 
DESIGN :
A Prospective Case Control Study. A total of 50 Diabetic and 50 age 
matched Non-diabetic control were selected and ECHO-Doppler study done.
The study was reviewed and approved by the Institutional Ethical 
Committee, Kilpauk Medical College and Hospital, Chennai.
METHODOLOGY : 
SUBJECT SELECTION : 
A. INCLUSION CRITERIA : 
Case : Diabetes mellitus patient
Control : Age-matched non Diabetic patients
B. EXCLUSION CRITERIA :
Patients with history of 
1) Age more than 65 years 
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2) Systemic hypertension 
3) Coronary artery disease 
4) Valvular heart disease 
5) Restrictive cardiomyopathy 
6) Hypertrophic obstructive cardiomyopathy 
7) Heart failure 
8) Pericardial disease 
9) Ejection Fraction less than 50% 
10) Blood Urea >40mg/dl & Serum creatinine >0.9mg/dl for 
females and >1.2 mg/dl for males. Diastolic Dysfunction was 
diagnosed in all selected 50 DM patients and Age matched 
controls using M mode ECHO-Doppler – Transmitral and 
pulmonary vein flow pattern. 
Definition of Diabetes mellitus : 
Patients were considered to be Diabetic if, 
 Individuals who are already on OHA'S or Insulin 
(or)
 Symptoms of Diabetic mellitus and Random blood sugar >
200mg/dl 
(or)
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 Fasting Plasma Glucose > 126 mg/dl 
(or)
 Two hour Plasma Glucose > 200 mg/dl during an OGTT.
Definition of Hypertension : 
Patients were considered to be Hypertensive when, 
 They were already on anti – HT medications 
(or)
 Documented BP of  > 140/90 mm of Hg on two or more 
occasions.
Definition of Dyslipidemia : 
Values were considered to be abnormal if; 
 Total Cholesterol > 200 mg/dl 
 LDL  >  100 mg/dl 
 HDL  < 40 mg/dl 
 TG' s  >  200 mg/dl 
Body Mass Index : 
BMI is considered abnormal if it is > 25 kg/m2
Urine Proteinuria : 
Abnormal if Urine protein by dipstick 2+ or more 
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STATISTICAL METHOD: 
Statistical Analysis was done by, 
 Chi square. 
 Two sample t test. 
 Binary Logistic Regression.
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OBSERVATION AND ANALYSIS
Total of 50 Diabetic and 50 Non Diabetic control were subjected to 
ECHO-Doppler study. The mean Age group of Diabetic was 54.38 and for   
Non – Diabetic was 53. There were 32 and 33 males & 18 and 17 females in 
Diabetic and Non – Diabetic group respectively. 
The variables in two groups were compared and various factors 
associated with Diastolic Dysfunction were analysed in Diabetic group.
The results are as follows, 
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COMPARISON BETWEEN DM AND NON-DM GROUP WITH
RESPECT TO:
1. AGE
2. SEX
3. ALCOHOL
4. SMOKING 
5. BMI 
6. DYSLIPIDEMIA
7. DIABETIC RETINOPATHY 
8. URINE PROTEIN 
9. ECHO DD
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MEAN AGE
The mean age of the DM group is 54.38 and Non-DM group is 53, 
which is not statistically significant.
DIABETIC NON-DIABETIC
MEAN AGE 54.38 53
p value : 0.176 ( >0.05 ) not significant                                            
DM NON-DM
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SEX
The sex distribution between DM and Non-DM group is depicted below 
and not statistically significant.
DIABETIC NON-DIABETIC
MALE 64.00% 66.00%
FEMALE 36.00% 34.00%
p value : 0.834  (>0.05 ) not significant
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ALCOHOL
The distribution of alcohol intake between DM and Non-DM group is 
depicted below and not statistically significant.
DIABETIC NON-DIABETIC
ALCOHOL 42.00% 40.00%
NON-ALCOHOL 58.00% 60.00%
p value : 0.839 (>0.05)  not significant.
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SMOKING
The distribution of tobacco smoking between DM and Non-DM group is 
depicted below and not statistically significant.
DIABETIC NON-DIABETIC
SMOKERS 58.00% 50.00%
NON-SMOKERS 42.00% 50.00%
p value : 0.422 (>0.05) not significant
Smokers Non-Smokers
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BMI
The Body mass index (mean value) of the DM and Non-DM group is 
29.78 and 28.64 respectively. It is statistically significant.
DIABETIC NON-DIABETIC
BMI (mean value) 29.78 28.64
p value : 0.030 (<0.05) significant
t-test
t-test for Equality of Means
P value
BMI Equal variances assumed .030
DM NON-DM
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DYSLIPIDEMIA (mean value)
The difference between mean value of TC, LDL and TG were 
statistically significant, and not so for HDL.
DIABETIC NON-DIABETIC
TOTAL CHOLESTEROL 234 178
LDL 153 105
HDL 34 38
TG 227 165
Total Chol LDL HDL TG
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t-test
F P value
TOTAL 
CHOLESTEROL
Equal variances assumed 6.489 .012
HDL Equal variances assumed 2.755 .100
LDL Equal variances assumed 10.274 .002
TG Equal variances assumed 5.990 0.02
GROUP N Mean Std. Deviation Std. Error Mean
TOTAL CHOLESTEROL DM 50 234.50 24.337 3.442
NON-
DM
50 176.80 17.643 2.495
HDL DM 50 34.96 2.432 .344
NON-
DM
50 38.28 2.061 .291
LDL DM 50 153.48 23.907 3.381
NON-
DM
50 105.44 15.450 2.185
TG DM 50 227.60 24.963 3.530
NON-
DM
50 165.04 36.850 5.21
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FUNDUS DR
In the DM group 32 had DR i.e. 64%, where as none had in Non-DM 
group. It is statistically significant.
DIABETIC RETINOPATHY DIABETIC NON-DIABETIC
PRESENT 64.00% 0.00%
ABSENT 36.00% 100.00%
p value: 0.000  (< 0.05 ) significant 
CHI-SQUARE TEST
Value df P value
Pearson Chi-Square 47.06 1 0
Present Absent
0
10
20
30
40
50
60
70
80
90
100
64
36
0
100
FUNDUS DR
DM
NON-DM
V
a
lu
e
s
 in
 %
59
URINE PROTEIN
In DM group 33 i.e. 66% had significant proteinuria where as in Non-
DM group 4 i.e. 8% had which is statistically significant.
URINE PROTEIN DIABETIC NON-DIABETIC
PRESENT 66.00% 8.00%
ABSENT 34.00% 92.00%
p value : 0.000 (<0.05)  significant 
                                  
CHI-SQUARE TEST
Value df P value
Pearson Chi-Square 36.08 1 0
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ECHO DD
In the DM group 30 i.e. 60% had Diastolic Dysfunction where as Non-
DM 7 i.e. 14% had DD, which is statistically significant.
ECHO DD DIABETIC NON-DIABETIC
PRESENT 60.00% 14.00%
ABSENT 40.00% 86.00%
p value : 0.000 (<0.05)  significant
                                      
CHI-SQUARE TEST
Value df P value
Pearson Chi-Square 22.69 1 0
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COMPARISON OF THE VARIABLES WITHIN DIABETIC 
GROUP : 
(1) WITH RESPECT TO AGE GROUP
p value : 0.077 ( >0.05) not significant
ECHO DD
In yrs ABSENT PRESENT Total
AGE GROUP 40 -50 Count 7 3 10
% of Total 14.0% 6.0% 20.0%
50 -60 Count 13 26 39
% of Total 26.0% 52.0% 78.0%
>60 Count 0 1 1
% of Total .0% 2.0% 2.0%
Total Count 20 30 50
% of Total 40.0% 60.0% 100.0%
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CHI-SQUARE TEST
Value df P value
Pearson Chi-Square 5.14 2 .077
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(2) WITH RESPECT TO SEX
ECHO DD
ABSENT PRESENT Total
SEX Female Count 7 11 18
% of Total 14.0% 22.0% 36.0%
Male Count 13 19 32
% of Total 26.0% 38.0% 64.0%
Total Count 20 30 50
% of Total 40.0% 60.0% 100.0%
p value 0.904 (>0.05) not significant
CHI-SQUARE TEST
Value df P value
Pearson Chi-Square 0.01 1 .904
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(3) WITH RESPECT TO DURATION OF DM
ECHO DD N Mean Std. Deviation Std. Error Mean
DURATION OF 
DIABETES
PRESENT 30 14.90 2.524 .461
ABSENT 20 7.55 1.432 0.32
p value  : 0.000 ( <0.05 ) significant 
CHI-SQUARE TEST
t-test for Equality of Means
df P value Mean difference
DURATION OF 
DIABETES
Equal variances assumed 48 .000 7.35
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(4)WITH RESPECT TO SMOKING
ECHO DD
ABSENT PRESENT Total
SMOKERS Count 7 14 21
% of Total 14.0% 28.0% 42.0%
NON 
SMOKERS
Count 13 16 29
% of Total 26.0% 32.0% 58.0%
Total Count 20 30 50
% of Total 40.0% 60.0% 100.0%
p value : 0.413 (>0.05) not significant
CHI-SQUARE TEST
Value df P value 
Pearson Chi-Square 0.67 1 .413
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(5)WITH RESPECT TO ALCOHOL
ECHO DD
ABSENT PRESENT Total
ALCOHOL _ Count 10 19 29
% of Total 20.0% 38.0% 58.0%
+ Count 10 11 21
% of Total 20.0% 22.0% 42.0%
Total Count 20 30 50
% of Total 40.0% 60.0% 100.0%
p value : 0.349 (>0.05) not significant
CHI-SQUARE TEST
Value df P value
Pearson Chi-Square 0.88 1 .349
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(6)WITH RESPECT TO BODY MASS INDEX (BMI)
ECHO DD N Mean Std. Deviation Std. Error Mean
BMI PRESENT 30 30.8560 1.44123 .26313
ABSENT 20 28.1605 2.55091 .57040
p value : 0.000 ( < 0.05 ) significant 
t-test
P value 
BMI Equal variances assumed .000
Equal variances not assumed .000
PRESENT ABSENT
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(7) WITH RESPECT TO DYSLIPIDEMIA
ECHO DD N Mean Std. Deviation Std. Error Mean
TOTAL 
CHOLESTEROL
PRESENT 30 245.50 20.953 3.825
ABSENT 20 218.00 19.488 4.358
HDL PRESENT 30 34.80 2.265 .414
ABSENT 20 35.20 2.707 .605
LDL PRESENT 30 164.93 21.635 3.950
ABSENT 20 136.30 15.550 3.477
TG PRESENT 30 232.53 23.825 4.350
ABSENT 20 220.20 25.389 5.68
t-test
t-test for Equality of Means
df P value Mean Difference
TOTAL 
CHOLESTEROL
Equal variances assumed 48 .000 27.500
HDL Equal variances assumed 48 .574 -.400
LDL Equal variances assumed 48 .000 28.633
TG Equal variances assumed 48 .087 12.333
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p value  for  Total chol : 0.000 ( <0.05 ) significant
p value for HDL : 0.574 (>0.05 ) not significant
p value  for LDL: 0.000 ( <0.05 ) significant 
p value  for TG : 0.087 (>0.05 ) not significant
TOTAL CHOL HDL LDL TG
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(8)WITH RESPECT TO DIABETIC RETINOPATHY
ECHO DD
ABSENT PRESENT Total
FUNDUS DR _ Count 18 0 18
% of Total 36.0% .0% 36.0%
+ Count 2 30 32
% of Total 4.0% 60.0% 64.0%
Total Count 20 30 50
% of Total 40.0% 60.0% 100.0%
p value : 0.000 ( <0.05 ) significant
                                                 CHI-SQUARE TEST
Value df P value
Pearson Chi-Square 42.19 1 .000
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(9) RESPECT TO URINE PROTEIN
ECHO DD
ABSENT PRESENT Total
URINE 
PROTEIN
_ Count 17 0 17
% of Total 34.0% .0% 34.0%
+ Count 3 30 33
% of Total 6.0% 60.0% 66.0%
Total Count 20 30 50
% of Total 40.0% 60.0% 100.00%
p value  : 0.000 ( <0.05 ) significant 
CHI-SQUARE TEST
Value df P value 
Pearson Chi-Square 38.64 1 .000
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In the Diabetic group, the following variables were significantly 
different from ECHO DD present and absent group. By using Binary Logistic 
regression, we came to know that all the following variables are not associated 
risk factors with respect to Diastolic Dysfunction. Even though the variables 
were significant with respect to Diastolic Dysfunction, they are not significant 
associated risk factors with respect to Diastolic Dysfunction. So  Diabetic 
itself, a risk factor for DD . 
AGE GROUP
DURATION OF DIABETES 
WEIGHT
BMI
FUNDUS DR
URINE PROTEIN
TOTAL CHOLESTEROL
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DISCUSSION
This study was conducted in individuals without HT, CAD and Heart 
failure, in 50 DM patients and 50 Age matched Non-DM controls. It was found 
that 30 of 50 DM patients had Diastolic Dysfunction whereas in Non-DM 
group, 7 out of 50 had DD. Age, Sex, Smoking and Alcohol were comparable 
between the two groups but Dyslipidemia, high BMI, Retinopathy, Proteinuria 
found to be more in the Diabetic group. From this study it was found that there 
was high prevalance of (60%) Diastolic Dysfunction in the diabetic 
individuals. This observation of high prevalence of DD in DM is consistent 
with several studies. In a community based study[165], 48% prevalence was 
found; Poirier et al,[119]found 60% prevalence and Zabalgoitia et al [120] found 
47% prevalence. In one another study a prevalence of 60% was found.[189] 
COMPARISON OF THE INDIVIDUAL VARIABLES WITH DD WITHIN 
THE DM GROUP 
1. Influence of Age on DD :
The individuals were divided into three age groups of 40-50, 50-60, >60, 
with 3/10, 26/39 and 1/1 [DD+ / total number in that group]. At first look, it 
appears that DD incidence increases with age but this is not statistically 
significant.
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2. Gender :
There were totally 32 males of whom 19 (59.35%) had DD and in 
females 11(61.11%) had DD of total 18, which is not statistically significant. 
Hence DD is equally distributed between both sexes.
3. Duration of DM : 
The DM group was divided into two groups based on the presence and 
absence of DD. The mean duration of DM in individuals with DD was 14.90 
years and for those without DD was 7.55 years which is statistically significant. 
This study shows that with increase in duration of DM there is more chance of 
developing DD. Many studies done in past have come to a similar conclusion 
[190 – 196]. Further it was also shown in studies that screening for DD after four 
years of diagnosing DM will increase its sensitivity. [197-199]
4. Smoking and Alcohol :
Among 21smokers 14 (66.67) had DD and in 29 non smokers 16(55.17) 
had DD which is not statistically significant. Similarly in 21 alcoholics 11 had 
DD and in 29 non alcoholics 19 had DD which is also not significant. Hence 
Smoking and Alcohol does not influence the development of DD in DM 
patients.
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5. Body mass Index :
The mean value of BMI in patients with diastolic dysfunction is 30.86 
and that of patients without diastolic dysfunction is 28.16. Hence it is 
statistically significant. Several previous studies have shown that there is 
higher incidence of DD in obese individuals. [200-202]
6. Association of Dyslipidemia with diastolic dysfunction :
In this study a significant association of DD with Total Cholesterol and 
LDL was found and not with HDL and TG's. Hence dyslipidemia particularly 
LDL cholesterol has been associated with DD in DM. Similar association was 
also found in previous studies [203].
7. Diabetic Retinopathy :
In this study, 32 individuals had DR of which 30 had diastolic 
dysfunction. It was found that no individual in the study population had DD in 
the absence of DR. Hence presence of diabetic retinopathy is strongly 
correlated to diastolic dysfunction. Studies performed in diabetic patients free 
of coronary artery disease, have demonstrated that patients with mild to severe 
retinopathy exhibited LV diastolic dysfunction (lower E/A values) compared to 
age-matched controls [114,127] or patients without retinopathy [123,128]. In the most 
recent report [129], a higher prevalence of retinopathy (49%) was encountered in 
patients with abnormal mitral filling pattern (E/A ratio < 1) compared to 
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patients with a normal diastolic function (20%). This relation with retinopathy 
was however not constantly found [118,130].
8. Association between Proteinuria and DD :
In this study, 33 individuals had significant proteinuria of which 30 had 
DD. It is highly significant. In a study done by Sampson et al [131], found that 
gradual decrease in E/A ratio in type 1 DM patients according to the presence 
of microalbuminuria and proteinuria. In another study conducted by Perez et al, 
[123] also observed similar finding. In type DM 1 patient with microalbuminuria 
demonstrated LV DD, whereas LV DD was not seen in patients without 
microalbuminuria in study done by Watschinger et al [131] and Guglielmi et al. 
[133]
Binary Logistic Regression : 
Eventhough, Duration of DM, BMI, dyslipidemia, DR and Proteinuria 
were significantly associated with DD, by BINARY LOGISTIC 
REGRESSION method it was found that they were not significant risk factors 
and DIABETES itself, a risk factor for DD.
77
SUMMARY
 In this study, diastolic dysfunction had 60% prevalence in Diabetic 
patients and 14% in case of Non-diabetic individuals. 
 It was seen that with increasing age, there was an increase in incidence 
of DD but it was found to be statistically insignificant.
 Gender, alcohol and smoking does not play any role in diastolic 
dysfunction.
 Duration of diabetes is a significant factor. With increasing duration of 
DM, there is increase in incidence of DD.
 Body Mass Index is a significant factor. There is higher incidence of DD 
in    individuals with elevated BMI.
 Dyslipidemia especially Total Cholesterol, LDL and Triglycerides were 
found to be associated with Diastolic dysfunction.
 Diabetic Retinopathy was found to be strongly correlated with diastolic 
dysfunction. No individual had DD in the absence of Diabetic 
retinopathy in the study population.
 Significant Proteinuria was also found to be associated with diastolic 
dysfunction. It was statistically significant.
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From Binary logistic regression, it was found that, eventhough, most of 
the variables were significant in relation to DD, they are not significant risk 
factors for DD. Hence Diabetes, itself a risk factor for Diastolic dysfunction.
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CONCLUSION
The study was conducted to find out Diastolic dysfunction in diabetic 
patients and to find out the variables associated with it. It was done by 
prospective case control study in Diabetology and cardiac care unit of GRH. 
The Statistical Analysis was done by 
 Chi-square test 
 Student t-test
 Binary Logistic Regression 
Among the 50 Diabetic patients, 30 (60%) had Diastolic dysfunction and 
in Non-diabetic group, 7(14%) had DD, which was statistically significant. 
Hence diabetes mellitus is associated with diastolic dysfunction. 
Among the other variables, diabetic retinopathy, proteinuria, 
dyslipidemia, elevated BMI were found to be associated with DM.
By comparing the presence and absence of DD within diabetic group, 
the following variables were found to be statistically significant and associated:
 Duration of Diabetes
 Body Mass Index 
 Diabetic retinopathy 
 Proteinuria
 Dyslipidemia 
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By Binary Logistic Regression method, DIABETES, itself a risk factor 
for diastolic Dysfunction.
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PROFORMA
Name Diabetic OP number
Age Occupation
Sex 
Personal Data
1. Smoking 
2. Alcohol 
3. Life style 
4. Duration of DM 
on OHA's or on Insulin 
5. Systemic hypertension 
6. Dyslipidemia 
7. Coronary Artery Disease 
8. Congestive Cardiac Failure 
9. Valvular Heart Disease 
10.Pericardial Disease / RCM / HOCM
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Physical Examination:
Height 
Weight 
BMI 
Pulse Rate 
Blood Pressure Systolic & Diastolic 
JVP 
CVS Heart Sounds & Murmurs Rub 
RS 
Diabetic Retinopathy
Lab Data:
Recent Blood Sugar Fasting/ PP / RBS
Fasting Lipid Profile
ECG
Urine Protein
ECHO
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ABBREVATIONS
LV - Left Ventricle
DP - Diastolic Pressure
DV - Diastolic Volume
ECM - Extra Cellular Matrix
BNP - Brain Natriuretic Peptide
HF - Heart Failure
NYHA - New York Heart Association 
LVH - Left Ventricular Hypertrophy 
DD - Diastolic Dysfunction 
Vp - Propagation velocity 
EF - Ejection Fraction 
IN-CHF - Italian Network on Congestive Heart Failure 
CHARM - Candesartan in Heart Failure Assessment of Reduction in 
Mortality 
CHF - Congestive Heart Failure 
OHA - Oral Hypoglycemic Agents 
DM - Diabetes Mellitus 
GRH - Government Royapettah Hospital 
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OGTT - Oral Glucose Tolerance Test 
TC - Total Cholesterol 
LDL - Low Density Cholesterol 
HDL  - High Density Cholesterol 
TG - Triglycerides 
w.r.t - with respect to 
DR - Diabetic Retinopathy
RCM - Restrictive Cardiomyopathy
HOCM - Hypertrophic Obstructive Cardiomyopathy
ECHO - Echocardiography
ECG - Electrocardiography
PP - Post Prandial
RBS - Random Blood Sugar
DHF - Diastolic Heart Failure
OPD - Out Patient Department
BP -  Blood Pressure
CAD - Coronary Artery Disease
JVP - Jugular Venous Pressure
PAS - Periodic Acid Schiff
HT - Hypertension
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ACEI - Angiotensin Converting Enzyme Inhibitors
AGE - Advanced-Glycated End products
BMI - Body Mass Index
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MASTER CHART - CASES
Sl.No Name Age Sex
Duration of 
DM Smoking Alcohol Pulse rate
Systolic 
BP
Diastolic 
BP Height Weight BMI
1 Munnusawmy 56 Male 18 + + 98 130 80 163 83 31.32
2 Samapath kumar 58 Male 16 + - 96 126 84 165 85 31.25
3 Kumari 60 Female 20 - - 90 124 80 155 80 33.33
4 Nagammal 53 Female 14 - - 86 114 70 151 78 34.21
5 Kanagavalli 48 Female 7 - - 80 110 70 158 72 28.8
6 Senguttuvan 50 Male 10 + + 82 124 80 170 88 30.45
7 Mohamed haseem 52 Male 9 + + 82 130 80 157 78 31.58
8 Rafi 58 Male 17 + + 90 132 80 166 82 29.71
9 Ravi 56 Male 15 + - 86 130 80 170 88 30.45
10 Irshad 53 Male 8 + + 80 130 80 167 85 30.47
11 Lakshmi 50 Female 13 - - 80 118 72 156 76 31.28
12 Gangabhai 59 Female 16 - - 82 130 80 154 75 31.65
13 Selvam 51 Male 8 + + 90 124 70 168 87 30.85
14 Thangadurai 57 Male 14 + - 80 130 80 172 80 30.41
15 Saraswathi 48 Female 6 - - 82 110 70 152 72 31.17
16 Mathivanan 50 Male 7 + - 84 130 80 156 76 31.28
17 Senthilkumar 47 Male 6 + + 80 130 80 160 80 31.25
18 Kasi 56 Male 15 + - 78 128 80 157 80 32.39
19 Paneerselvam 60 Male 16 + + 82 130 80 162 82 31.29
20 Nagaraj 58 Male 15 - - 72 124 80 159 80 31.62
21 Meenakshi 55 Female 13 - - 88 130 84 154 72 30.37
22 Shankar 56 Male 18 + + 86 126 80 164 80 29.74
23 Ganesan 54 Male 12 + + 82 110 80 164 83 30.85
24 Parameshwari 50 Female 14 - - 84 110 70 153 77 32.89
25 Balasundharam 52 Male 15 + + 86 126 80 165 80 29.38
26 Maheshwari 52 Female 8 - - 90 120 70 160 65 25.39
27 Murugan 52 Male 6 + + 86 124 80 165 70 25.7
28 Rajeshwari 50 Female 13 - - 86 126 84 155 68 28.3
29 Palani 54 Male 15 + + 90 120 80 169 85 29.76
30 Ramesh 48 Male 4 + + 84 116 80 172 78 26.12
31 Amsa 54 Female 8 - - 82 110 84 157 62 25.15
32 Sivaprakasam 58 Male 16 + - 82 120 76 162 80 30.48
33 Thangavel 60 Male 19 - - 76 126 80 166 86 31.2
34 Bhargavi 58 Female 9 - - 80 110 80 157 68 27.59
35 Vadivel 60 Male 17 + + 74 120 76 171 90 31.14
36 Chellamal 54 Female 13 - - 80 116 80 151 67 29.38
37 Prakasam 58 Male 7 + + 76 120 80 169 76 26.61
38 Dhanapal 62 Male 20 + + 76 126 80 170 88 30.45
39 Samundeshwari 56 Female 14 - - 84 130 78 158 78 31.25
40 Sivakumar 56 Male 6 + - 82 126 84 178 89 28.09
41 Kuppamal 54 Female 12 - - 80 130 82 157 78 31.64
42 Ismael 46 Male 8 + + 84 126 80 169 87 30.46
43 Subramaniam 53 Male 12 - - 86 120 84 174 95 31.38
44 Kotteshwari 55 Female 11 - - 80 130 80 155 77 32.05
45 Lakshmanan 56 Male 9 + + 78 124 76 172 75 25.35
46 Shankaran 53 Male 10 + + 86 116 80 175 83 27.1
47 Jansirani 58 Female 9 - - 76 110 76 153 60 25.63
48 Shajahan 56 Male 8 + - 80 126 76 168 76 26.93
49 Amudha 53 Female 8 - - 82 120 74 157 60 24.34
50 Bhaskar 56 Male 14 + + 84 124 80 170 85 29.41
Fundus 
DR
Urine 
albumin
Total 
Cholesterol HDL LDL TG
ECHO 
DD
+ 2+ 244 32 180 260 Present
+ 2+ 234 32 150 260 Present
+ 2+ 235 30 152 265 Present
+ 2+ 229 30 152 236 Present
- trace 207 30 130 236 Absent
+ Nil 219 38 130 254 Absent
- 1+ 220 32 140 240 Absent
+ 2+ 233 36 148 245 Present
+ 2+ 232 36 146 252 Present
- Nil 224 34 140 252 Absent
+ 2+ 231 34 148 245 Present
+ 2+ 228 36 144 240 Present
- Nil 219 34 136 244 Absent
+ 2+ 229 34 144 254 Present
- 2+ 218 32 138 238 Absent
- Nil 221 30 140 256 Absent
- 2+ 260 32 138 222 Absent
+ 2+ 228 34 144 250 Present
+ 2+ 229 34 144 255 Present
+ 2+ 227 32 146 246 Present
+ 2+ 285 36 202 236 Present
+ 2+ 272 36 188 240 Present
+ 2+ 233 38 156 195 Present
+ 2+ 285 34 208 216 Present
+ 2+ 242 40 160 210 Present
- Nil 200 36 124 198 Absent
- Nil 208 36 128 218 Absent
+ 2+ 264 36 186 212 Present
+ 2+ 256 34 180 210 Present
- Nil 214 38 134 208 Absent
- Nil 202 38 128 178 Absent
+ 2+ 268 34 190 220 Present
+ 2+ 275 34 198 214 Present
- Nil 222 36 146 200 Absent
+ 2+ 276 36 192 242 Present
+ 2+ 264 36 178 252 Present
- 1+ 220 36 146 188 Absent
+ 2+ 257 34 172 256 Present
+ 2+ 237 38 158 206 Present
- Nil 266 38 184 222 Absent
+ 2+ 262 34 182 228 Present
+ 2+ 240 36 160 218 Absent
+ 2+ 255 36 180 195 Present
+ 2+ 232 34 146 260 Present
- Nil 184 38 110 180 Absent
+ 2+ 209 38 132 196 Present
- Nil 208 36 130 210 Absent
- Nil 212 36 124 250 Absent
- Nil 196 38 120 192 Absent
+ 2+ 214 36 142 180 Present
MASTER CHART - CONTROL
Sl. No Name Age Sex Smoking Alcohol Pulse rate
Systolic 
BP
Diastolic 
BP Height Weight BMI
Fundus 
retinopathy
1 Lakshmi 48 Female - - 86 120 80 155 58 24.17 -
2 Mahalakshmi 51 Female - - 88 130 90 152 54 23.38 -
3 Kesavan 56 Male + + 78 124 82 158 74 29.6 -
4 Murugan 47 Male - - 84 136 74 160 78 30.47 -
5 Sundharam 55 Male + + 88 132 82 156 80 32.92 -
6 Fatima 52 Female - - 90 130 80 153 62 26.5 -
7 Vimalakumari 46 Female - - 86 120 80 149 56 25.23 -
8 Gopal 58 Male + + 84 130 86 158 80 32.13 -
9 Mariammal 49 Female - - 78 110 70 150 61 27.11 -
10 Kathiravan 44 Male + + 82 130 80 158 78 31.2 -
11 Manivannan 58 Male + - 76 134 86 160 75 29.3 -
12 Selvam 54 Male - - 78 128 80 153 80 34.19 -
13 Manimeghalai 47 Female - - 84 110 70 152 60 25.97 -
14 Govindhaswamy 48 Male + - 88 130 80 162 82 31.29 -
15 Perumal 53 Male + + 86 130 80 168 85 30.14 -
16 Sasikala 56 Female - - 76 120 70 154 58 24.47 -
17 Ahmed 60 Male - - 74 130 84 175 88 28.76 -
18 Rani 45 Female - - 86 110 70 150 56 24.89 -
19 Sundharavadivel 46 Male + + 80 134 80 156 82 33.74 -
20 Gandhimathy 52 Female - - 90 130 80 148 68 31.05 -
21 Velu 44 Male + + 76 130 86 150 72 32 -
22 Marimuthu 49 Male + + 76 126 80 158 80 32 -
23 Kumar 51 Male + + 82 120 80 165 77 28.31 -
24 Pushpa 62 Female - - 80 110 70 153 58 24.79 -
25 Latha 65 Female - - 84 110 70 152 56 24.24 -
26 Sundhramoorthy 63 Male - - 80 130 80 157 68 27.64 +
27 Kumaravel 58 Male + + 82 120 80 162 75 28.62 -
28 Hussain 56 Male + - 78 130 80 166 84 30.43 -
29 Nazar 49 Male + + 78 136 84 174 88 29.04 -
30 Natesan 54 Male - + 80 120 76 165 76 27.94 -
31 Ponnuswamy 58 Male - - 76 130 82 158 72 28.8 -
32 Muthuvadivel 45 Male + + 76 130 80 155 74 30.83 -
33 Ravikumar 49 Male + - 82 134 84 162 75 28.63 -
34 Sultan 53 Male + - 80 128 80 175 91 29.74 -
35 Deepak 57 Male + + 80 120 80 171 80 27.4 -
36 Selvaraj 48 Male + + 74 120 70 158 78 31.2 -
37 Palani 61 Male - - 78 130 80 155 76 31.67 -
38 Anbu 58 Male + + 78 130 82 158 75 30 -
39 Padmavathy 64 Female - - 92 110 80 149 56 25.23 -
40 Zaheer 46 Male - - 84 120 80 166 76 27.54 -
41 Palaniswamy 43 Male + + 80 130 80 164 80 29.74 -
42 Balakrishnan 55 Male + + 74 130 82 158 72 28.8 -
43 Vasanthi 49 Female - - 76 110 80 151 56 24.56 -
44 Kannnayiram 50 Male + + 84 134 82 159 75 29.64 -
45 Suseela 59 Female - - 88 128 80 152 74 32.03 -
46 Narayanan 52 Male + - 72 130 80 163 72 27.07 -
47 Savithri 60 Female - - 80 110 70 152 60 25.97 -
48 Devanantham 57 Male + + 78 120 80 160 73 28.52 -
49 Madhini 46 Female - - 78 120 70 153 69 29.49 -
50 Kuppammal 64 Female - - 86 130 80 148 52 23.74 -
Urine 
albumin
Total 
Cholesterol HDL LDL TG ECHO DD
Nil 189 38 120 156 Absent
Nil 176 40 100 180 Absent
Nil 184 38 110 180 Absent
1+ 240 36 160 218 Absent
Nil 208 36 130 210 Absent
Nil 184 38 126 98 Absent
Nil 174 40 108 128 Absent
Nil 212 36 124 250 Present
Nil 156 34 98 122 Absent
1+ 196 38 120 192 Absent
Nil 214 38 134 208 Absent
Nil 169 36 98 176 Absent
Nil 172 38 102 162 Absent
Nil 177 40 110 133 Absent
Nil 198 40 122 180 Absent
1+ 194 36 120 188 Absent
Nil 162 34 88 200 Present
Nil 158 38 96 122 Absent
Nil 177 34 96 235 Absent
2+ 172 36 100 182 Absent
Nil 179 40 108 155 Absent
Nil 162 40 94 142 Absent
Nil 190 38 128 118 Absent
Nil 180 38 112 148 Absent
Nil 166 40 86 198 Present
Nil 157 38 92 135 Present
2+ 158 38 88 162 Absent
Nil 178 40 98 200 Absent
Nil 172 36 100 182 Absent
Nil 180 38 110 160 Absent
Nil 168 38 96 168 Absent
1+ 163 36 98 144 Absent
Nil 164 40 100 118 Absent
Nil 146 38 88 100 Absent
Nil 167 38 92 184 Absent
Nil 166 36 98 158 Absent
Nil 174 40 112 110 Present
2+ 180 40 104 178 Absent
Nil 169 38 94 184 Present
Nil 178 38 118 112 Absent
Nil 210 40 128 210 Absent
Nil 167 42 106 96 Absent
Nil 168 40 90 192 Absent
1+ 168 40 92 178 Absent
Nil 166 38 84 220 Absent
Nil 158 38 84 180 Absent
Nil 175 44 98 166 Absent
Nil 184 38 112 170 Absent
2+ 176 40 110 128 Absent
Nil 159 42 90 136 Present
